Clinomics, Inc. engages in the development and commercializing cancer and disease early diagnosis technology services. Its products and services include COVID-19 test kits, liquid biopsy and precision medicine, health care, and big data. The company was founded on June 21, 2011 and is headquartered in Ulsan, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company